Acta Pharmacol Sin. 2022 Apr 6. doi: 10.1038/s41401-022-00893-8. Online ahead of print.(IF:6.150).
2022-04-06Acta Pharmacol Sin. 2022 Apr 6. doi: 10.1038/s41401-022-00893-8. Online ahead of print. Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9 (IF:6.150).